Search for content, post, videos

Diamyd Medical receives patent protection in the US and Japan

Ulf Hannelius

The US Patent and Trademark Office (USPTO) and the Japanese Patent Office have informed Diamyd Medical that they will grant the patent for the company’s oral formulation of the GABA-based study drug Remygen.

Remygen is currently in Phase 2 development through the ReGenerate-1 trial in individuals with long-term Type 1 Diabetes. Results are expected later this quarter.

“The ongoing phase 2 trial ReGenerate-1 will guide us on how to move forward with Remygen,” says Ulf Hannelius, CEO of Diamyd Medical. “Patent protection for the formulation is important for all possible routes forward, especially for commercially important geographies such as the US and Japan.”

In addition to the Remygen formulation patent, Diamyd Medical holds an exclusive license from the University of California, Los Angeles (UCLA), for treating diabetes and other inflammatory disorders with GABA alone and in certain combinations including GABA receptor modulators and antigen-specific immunotherapies, the company states. Diamyd Medical has also filed patents on GABA’s therapeutic effect on the hormonal counter-regulatory response to low blood sugar levels.

Photo of Ulf Hannelius: Diamyd